# Regeneron Pharmaceuticals Inc. (REGN)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $65.34B  
**Price:** $601.65 (-2.36%)

> Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio includes treatments such as Eylea and Eylea HD for retinal and eye disorders, Dupixent for inflammatory and allergic conditions, Praluent for cholesterol management, Libtayo in oncology, and Kevzara for rheumatoid arthritis. Regeneron also works on antibody-based medicines and collaborates with partners on advanced research programs, supporting a broad pipeline of therapies. The company serves patients, healthcare providers, and medical systems through prescription medicines used in specialist and hospital care settings. Headquartered in Tarrytown, New York, Regeneron plays a significant role in the biotechnology market by combining drug development, manufacturing, and commercialization across multiple therapeutic areas.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $14.34B | — | $3.58B | $4.50B | $41.48 |
| 2024 | $14.20B | — | $3.99B | $4.41B | $38.34 |
| 2023 | $13.12B | — | $4.05B | $3.95B | $34.77 |
| 2022 | $12.17B | — | $4.74B | $4.34B | $38.22 |
| 2021 | $16.07B | — | $8.95B | $8.08B | $71.97 |
| 2020 | $8.50B | — | $3.58B | $3.51B | $30.52 |
| 2019 | $6.56B | $6.15B | $2.21B | $2.12B | $18.46 |
| 2018 | $5.15B | $4.91B | $2.53B | $2.44B | $21.29 |
| 2017 | $5.87B | $5.67B | $2.08B | $1.20B | $10.34 |
| 2016 | $4.86B | $4.67B | $1.33B | $896M | $7.70 |
| 2015 | $4.10B | $3.86B | $1.25B | $636M | $5.52 |
| 2014 | $2.82B | $2.69B | $824M | $338M | $2.98 |
| 2013 | $2.10B | $1.99B | $743M | $414M | $3.72 |
| 2012 | $1.38B | $1.29B | $458M | $750M | $6.75 |
| 2011 | $446M | $442M | -$205M | -$222M | $-2.45 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $40.56B | $9.30B | $31.26B | $3.12B | $1.99B |
| 2024 | $37.76B | $8.41B | $29.35B | $2.49B | $1.98B |
| 2023 | $33.08B | $7.11B | $25.97B | $2.73B | $1.98B |
| 2022 | $29.21B | $6.55B | $22.66B | $3.11B | $1.98B |
| 2021 | $25.43B | $6.67B | $18.77B | $2.89B | $1.98B |
| 2020 | $17.16B | $6.14B | $11.03B | $2.19B | $1.98B |
| 2019 | $14.81B | $3.72B | $11.09B | $1.62B | — |
| 2018 | $11.73B | $2.98B | $8.76B | $1.47B | — |
| 2017 | $8.76B | $2.62B | $6.14B | $813M | — |
| 2016 | $6.97B | $2.52B | $4.45B | $535M | — |
| 2015 | $5.61B | $1.95B | $3.65B | $809M | — |
| 2014 | $3.84B | $1.29B | $2.55B | $649M | — |
| 2013 | $2.95B | $999M | $1.96B | $536M | — |
| 2012 | $2.08B | $835M | $1.26B | $230M | — |
| 2011 | $1.32B | $838M | $486M | $484M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $4.98B | — | — |
| 2024 | $4.42B | — | — |
| 2023 | $4.59B | — | — |
| 2022 | $5.01B | — | — |
| 2021 | $7.08B | — | — |
| 2020 | $2.62B | — | — |
| 2019 | $2.43B | — | — |
| 2018 | $2.20B | — | — |
| 2017 | $1.31B | — | — |
| 2016 | $1.49B | — | — |
| 2015 | $1.33B | — | — |
| 2014 | $752M | — | — |
| 2013 | $589M | — | — |
| 2012 | -$75M | — | — |
| 2011 | -$142M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/REGN)